Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-510"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-21"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance of medicinal products (amendment of Regulation (EC) No 726/2004) - Pharmacovigilance (amendment of Directive 2001/83/EC) (debate)2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20100921.18.2-510"2
lpv:hasSubsequent	lp_eu:2010-09-21-Speech-2-5112
lpv:speaker	lp:Dominique Riquet2
lpv:spokenAs	substitute; TRAN (2009-09-01--2012-01-18)3 member; EPP (2009-07-14--2014-06-30)3 substitute; Delegation for relations with the countries of Southeast Asia and the Association of Southeast Asian Nations (ASEAN) (2009-09-16--2014-06-30)3 member; Delegation to the EU-Russia Parliamentary Cooperation Committee (2009-09-16--2014-06-30)3 member; BUDG (2009-07-16--2012-01-18)3 unknown; Union pour un Mouvement Populaire - Parti Radical (2009-07-14--2012-01-10)3
lpv:translated text	"Mr President, Commissioner, I should like to take the floor briefly, first of all, to congratulate everyone who worked on this subject, and then to express my surprise, nonetheless, that one point has been overlooked, namely cross-pharmacovigilance. In fact, vertically, from the point of view of a single product, the report is extremely exhaustive, and the work that has been done is remarkable. Nevertheless, most problems are caused by the cumulative effect of medicinal products, as, in 92% of cases, patients receive multiple treatments. A medicinal product which, vertically, has no particular side effects, could have highly toxic side effects if crossed with another medicinal product. It is vital that we have access to a database on the cross effects of medicinal products, and it should, moreover, be made available to professionals and patients alike. This is all the more necessary given that many patients take prescription medicines and then self-medicate also, without having any information, in general, on the potential for highly toxic cross effects. I think that this issue has been touched on, but not dealt with, which is a great pity."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph